PMID- 37323693
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 2766-2098 (Electronic)
IS  - 2766-8509 (Print)
IS  - 2766-2098 (Linking)
VI  - 1
IP  - 3
DP  - 2021 Dec
TI  - Ultrasound-controlled drug release and drug activation for cancer therapy.
PG  - 20210023
LID - 10.1002/EXP.20210023 [doi]
LID - 20210023
AB  - Traditional chemotherapy suffers from severe toxicity and side effects that limit 
      its maximum application in cancer therapy. To overcome this challenge, an ideal 
      treatment strategy would be to selectively control the release or regulate the 
      activity of drugs to minimize the undesirable toxicity. Recently, ultrasound 
      (US)-responsive drug delivery systems (DDSs) have attracted significant attention 
      due to the non-invasiveness, high tissue penetration depth, and spatiotemporal 
      controllability of US. Moreover, the US-induced mechanical force has been proven 
      to be a robust method to site-selectively rearrange or cleave bonds in 
      mechanochemistry. This review describes the US-activated DDSs from the 
      fundamental basics and aims to present a comprehensive summary of the current 
      understanding of US-responsive DDSs for controlled drug release and drug 
      activation. First, we summarize the typical mechanisms for US-responsive drug 
      release and drug activation. Second, the main factors affecting the ultrasonic 
      responsiveness of drug carriers are outlined. Furthermore, representative 
      examples of US-controlled drug release and drug activation are discussed, 
      emphasizing their novelty and design principles. Finally, the challenges and an 
      outlook on this promising therapeutic strategy are discussed.
CI  - (c) 2021 The Authors. Exploration published by Henan University and John Wiley & 
      Sons Australia, Ltd.
FAU - Tu, Li
AU  - Tu L
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research School of 
      Pharmaceutical Sciences Xiamen University Xiamen P. R. China.
FAU - Liao, Zhihuan
AU  - Liao Z
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research School of 
      Pharmaceutical Sciences Xiamen University Xiamen P. R. China.
FAU - Luo, Zheng
AU  - Luo Z
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research School of 
      Pharmaceutical Sciences Xiamen University Xiamen P. R. China.
FAU - Wu, Yun-Long
AU  - Wu YL
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research School of 
      Pharmaceutical Sciences Xiamen University Xiamen P. R. China.
FAU - Herrmann, Andreas
AU  - Herrmann A
AD  - DWI - Leibniz Institute for Interactive Materials Aachen Germany.
AD  - Institute of Technical and Macromolecular Chemistry RWTH Aachen University Aachen 
      Germany.
FAU - Huo, Shuaidong
AU  - Huo S
AUID- ORCID: 0000-0003-3590-044X
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research School of 
      Pharmaceutical Sciences Xiamen University Xiamen P. R. China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211228
PL  - China
TA  - Exploration (Beijing)
JT  - Exploration (Beijing, China)
JID - 9918383883006676
PMC - PMC10190934
OTO - NOTNLM
OT  - cancer therapy
OT  - drug activation
OT  - drug release
OT  - mechanical force
OT  - ultrasound
COIS- There are no conflicts to declare.
EDAT- 2021/12/28 00:00
MHDA- 2021/12/28 00:01
PMCR- 2021/12/28
CRDT- 2023/06/16 04:01
PHST- 2021/09/22 00:00 [received]
PHST- 2021/12/02 00:00 [accepted]
PHST- 2021/12/28 00:01 [medline]
PHST- 2021/12/28 00:00 [pubmed]
PHST- 2023/06/16 04:01 [entrez]
PHST- 2021/12/28 00:00 [pmc-release]
AID - EXP240 [pii]
AID - 10.1002/EXP.20210023 [doi]
PST - epublish
SO  - Exploration (Beijing). 2021 Dec 28;1(3):20210023. doi: 10.1002/EXP.20210023. 
      eCollection 2021 Dec.